Back

Long-standing response to calcium channel blocker therapy on patients with various types of pulmonary hypertension: a systematic review and meta analysis.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Impact of pulmonary hypertension on quality of life and survival Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Yanka Dalmolin Salton

Florianopolis (Brazil)

7 More presentations in this session

Presentation thumbnail
Comparison of pulmonary arterial risk assessment tools to predict mortality or morbidity in treatment naive and previously diagnosed patients.
Doctor C. Fauvel (Rouen, FR)
Abstract Slides Video
Presentation thumbnail
Prognostic value of follow-up hemodynamics after initial treatment in pulmonary arterial hypertension
Doctor D. Guarino (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Multiparametric risk predictions for morbidity and mortality in patients with pulmonary arterial hypertension: insights from a nation-wide registry
Professor C. Kaymaz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Acute vasoreactivity testing for severe pulmonary hypertension associated with lung disease
Doctor R. Takano (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Health care utilisation in patients with mild pulmonary hypertension - EVIDENCE-PAH UK study
Doctor N. Karia (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Impact of pulmonary hypertension on quality of life and survival

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Cardiopulmonary exercise testing in long-term calcium channel blockers responders, does it normalize in the same way as pulmonary vascular resistance?
thumbnail
Congress Presentation
Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL).
thumbnail
Congress Presentation
Evaluating the safety and long-term efficacy of triple vasodilator therapy for pulmonary arterial hypertension associated with congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources